×
About 1,015 results

ALLMedicine™ Hyperoxaluria Center

Research & Reviews  367 results

Clinical Outcomes and Histological Patterns in Oxalate Nephropathy due to Enteric and N...
https://doi.org/10.1159/000520286
American Journal of Nephrology; Reddy S, Bolen E et. al.

Nov 30th, 2021 - Current knowledge of risk factors and renal histologic patterns of oxalate nephropathy (ON) not due to primary hyperoxaluria (PH) has been limited to small case series and case reports. Thus, we analyzed and compared clinical risk factors, histolo...

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
https://clinicaltrials.gov/ct2/show/NCT03847090

Nov 16th, 2021 - This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study. This study is designed to determine the short- and long-term efficacy of reloxaliase in terms of reducing urinary oxalate excretion and clinical benefits ...

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
https://clinicaltrials.gov/ct2/show/NCT04125472

Nov 11th, 2021 - Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact t...

see more →

Guidelines  1 results

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and ...
https://doi.org/10.1093/ndt/gfs078
Nephrology, Dialysis, Transplantation : Official Publicat... Cochat P, Hulton SA et. al.

May 2nd, 2012 - Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  18 results

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
https://clinicaltrials.gov/ct2/show/NCT03847090

Nov 16th, 2021 - This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study. This study is designed to determine the short- and long-term efficacy of reloxaliase in terms of reducing urinary oxalate excretion and clinical benefits ...

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
https://clinicaltrials.gov/ct2/show/NCT04125472

Nov 11th, 2021 - Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact t...

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Patients With Primary Hyperoxaluria Type 1
https://clinicaltrials.gov/ct2/show/NCT03350451

Nov 10th, 2021 - The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in patients with Primary Hyperoxaluria Type 1.

Plasma Oxalate in Patient With Short Bowel
https://clinicaltrials.gov/ct2/show/NCT04119765

Apr 26th, 2021 - Hyperoxaluria due to fat malabsorption is seen in patients suffering from short bowel and can lead to stones and nephrocalcinosis. Not all patients are prone to these renal complications. only urinary oxaluria is measured in practice. Plasma oxala...

Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis
https://clinicaltrials.gov/ct2/show/NCT02000219

Jan 25th, 2021 - The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering plasma oxalate levels in patients with primary hyperoxaluria who are on dialysis.

see more →

News  17 results

Lumasiran Effects in Rare Disease Seen Despite Kidney Status
https://www.medscape.com/viewarticle/962578

Nov 9th, 2021 - Lumasiran has shown benefit in reducing plasma oxalate in patients with primary hyperoxaluria type 1 (PH1) and severely impaired kidney function, according to new research.  Lumasiran (Oxlumo, Alnylam Pharmaceuticals), an RNA interference (RNAi) t...

Future 'Exceedingly Bright' for Kidney Stone Prevention
https://www.medscape.com/viewarticle/958630

Sep 13th, 2021 - Gene therapy, new therapeutics currently in clinical trials, and a promising dietary supplement are feeding the optimism of kidney stone expert Glenn Preminger, MD. Glenn Preminger "The future of kidney stones looks exceedingly bright," said Premi...

Fast Five Quiz: Primary Hyperoxaluria Type 1 Management
https://reference.medscape.com/viewarticle/944415

Mar 1st, 2021 - Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disease that is caused by a functional defect of alanine:glyoxylate aminotransferase catalysis, resulting in the overproduction of oxalate. The clinical impact of PH1 can be devastat...

Fast Five Quiz: Primary Hyperoxaluria Type 1 Screening and Diagnosis
https://reference.medscape.com/viewarticle/944411

Mar 1st, 2021 - Primary hyperoxaluria (PH) encompasses a group of rare genetic metabolic disorders that are characterized by the accumulation of oxalate in the kidneys and other organs. PH is categorized as type 1 (PH1), type 2 (PH2) or type 3 (PH3). An estimated...

FDA Clears First Drug to Treat Ultra-Rare Metabolic Disorder
https://www.medscape.com/viewarticle/941520

Nov 24th, 2020 - The US Food and Drug Administration (FDA) has approved lumasiran (Oxlumo, Alnylam Pharmaceuticals) subcutaneous injection to treat children and adults with primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder that causes recurrent ki...

see more →

Patient Education  2 results see all →